XEN 901

Drug Profile

XEN 901

Alternative Names: XEN-901

Latest Information Update: 21 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xenon Pharmaceuticals
  • Class Antiepileptic drugs; Small molecules
  • Mechanism of Action Nav1.6 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy
  • Preclinical Dravet syndrome

Most Recent Events

  • 21 May 2018 Pharmacokinetic and adverse events data from a phase I trial in Healthy volunteers released by Xenon
  • 21 May 2018 Safety and pharmacodynamics data from a preclinical trial in Epilepsy released by Xenon
  • 20 Feb 2018 Phase-I clinical trials in Epilepsy (In healthy volunteers) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top